|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis <ce:link locator='fx1'/>显示文摘 | Arun J. Sanyal Robert J. Fontana Adrian M. Di Bisceglie James E. Everhart Michael C. Doherty Gregory T. Everson John A. Donovan Peter F. Malet Savant Mehta Muhammad Y. Sheikh Andrea E. Reid Marc G. Ghany David R. Gretch the HALT-C Trial Group | 2006 | Gastrointestinal Endoscopy2006，，6： | 2 |
| 2 | Management of recurrent and persistent metastatic lymph nodes in well‐differentiated thyroid cancer: A multifactorial decision‐making guide for the thyroid cancer care collaborative显示文摘 | Mark L. Urken Mira Milas Gregory W. Randolph Ralph Tufano Donald Bergman Victor Bernet Elise M. Brett James D. Brierley Rhoda Cobin Gerard Doherty Joshua Klopper Stephanie Lee Josef Machac Jeffrey I. Mechanick Lisa A. Orloff Douglas Ross Robert C. Smallri | 2015 | Head Neck2015，，4： | 1 |
| 3 | Price Regulation in Property-Liability Insurance: A Contingent-Claims Approach 显示文摘 | Nell A Doherty James R Garven | 1986 | The Journal of Finance1986，，： | 1 |
| 4 | AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans显示文摘 | Biljana Georgievska Johan Sandin James Doherty Anette M?rtberg Jan Neelissen Anita Andersson Susanne Gruber Yvonne Nilsson P?r Sch?tt Per I. Arvidsson Sven Hellberg Gunilla Osswald Stefan Berg Johanna F?lting Ratan V. Bhat | 2013 | J Neurochem2013，，3： | 1 |
| 5 | Lithiated Porous Aromatic Frameworks with Exceptional Gas Storage Capacity显示文摘 | Kristina Konstas James W. Taylor Aaron W. Thornton Cara M. Doherty Wei Xian Lim Timothy J. Bastow Danielle F. Kennedy Colin D. Wood Barry J. Cox James M. Hill Anita J. Hill Matthew R. Hill | 2012 | Angew. Chem. Int. Ed2012，，27： | 1 |
| 6 | Connective tissue growth factor (CTGF) expression modulates response to high glucose 显示文摘 | James LR Le C Doherty H | 2013 | PLoSOne2013，8，70： | 1 |
| 7 | Vertebrate pesticide risk assessment by indigenous communities in New Zealand显示文摘In New Zealand,the vertebrate pesticide sodium fluoroacetate(Compound 1080)is aerially applied in baits for control of the brush-tailed possum Trichosurus vulpecula(Kerr,1792).Maori,the indigenous people of New Zealand,have raised concerns about 1080 impacts on culturally-important species.Here,we outline two steps taken to help Maori assess 1080 risk.First,field research was undertaken to determine if naturally-occurring plants utilized by a Maori community for food and medicine would take up 1080 from baits.Single baits were placed at the base of individual plants of two species,pikopiko(Asplenium bulbiferum)and karamuramu(Coprosma robusta).Plants were sampled at various times up to 56 days,and samples were analyzed for 1080 content.No 1080 was detected in any of the pikopiko samples,whereas 1080 was detected in karamuramu,at a maximum concentration of 5 ppb after seven days,and 2.5 ppb after 14 days.This concentration decreased to 0 at 28 days,indicating that 1080 was not persistent.The results of the present study suggest there is negligible risk of humans being poisoned by consum-ing plants that have taken up 1080 from baits.To allay community concerns that minute concentrations of 1080 might influence the medicinal properties of plants,it is suggested that a withholding period of 30 days after 1080 control operations could be adopted.Second,after further consultation we undertook a review of the scientific literature relating to 1080 impacts on additional non-target species of cultural importance to Maori.The information was presented on an interactive foodweb database that allowed the collection and presentation of a large volume of complex information about 1080 in a holistic and pictorial fashion.This database was presented to many Maori communities throughout New Zealand,and feedback was overwhelmingly positive.The database is likely to play a key role in informing these communities about 1080,and is seen as an important new tool to help these communities make their own risk assessments. | Shaun C.OGILVIE James M.ATARIA James WAIWAI James DOHERTY Aroha MILLER James G.ROSS Charles T.EASON | 2010 | Integrative Zoology2010，5，1： | 0 |
| 8 | 胆固醇酯转运蛋白抑制剂anacetrapib对血脂异常患者脂蛋白及健康个体24h动态血压的影响:2项双盲、随机、安慰剂对照Ⅰ期研究显示文摘背景抑制胆固醇酯转运蛋白(CETP)被认为有望成为治疗血脂异常的一种新策略。Anacetrapib(MK-0859)是目前正在研发的一种CETP抑制剂。本研究旨在评估anacetrapib作为单一治疗对低密度脂蛋白胆固醇(LDL—C)和高密度脂蛋白胆固醇(HDL-C)以及24h动态血压的影响。
方法作者进行了两项双盲、随机、安慰剂对照Ⅰ期研究。第一项研究中,50例年龄18~75岁的血脂异常患者(LDL—C1000~1900mg/L;治疗组40例,安慰剂组10例)接受anacetrapib治疗,剂量分别为每日餐后口服0mg、10mg、40mg、150mg或300mg,连续28d。采用标准的脂质和脂蛋白监测以及安全性监测,同时测定anacetrapib浓度进行药代动力学分析。第二项研究中,22例年龄为45~75岁的健康受试者接受每日餐后口服anacetrapib150mg或等量安慰剂治疗,连续10d,然后随机交换接受另一种治疗方法,各治疗期之间至少有14d洗脱期。研究过程中,每个治疗期的前1天和第10天进行24h动态血压监测。通过监测临床不良反应、体格检查、生命体征、12导联心电图和实验室安全性来评估两项研究安全性和耐受性的主要终点或次要终点。统计分析方法的选择符合方案分析。这两项试验均在ClinicalTrials.gov进行了注册,注册号分别为NCT00565292和NCT00565006。
结果血脂异常研究中,1例患者撤回知情同意书,1例因没有完整的服药前测定结果而在分析HDL—C和LDL—C数据时被剔除。Anacetrapib具有剂量依赖性调脂作用,对血脂异常患者其最大调脂作用为HDL—C增加129%[x=511(s=38)~x=1149(s=79)mg/L],而LDL-C降低38%[x=1382(s=114)~x=776(s=79)mg/L]。健康个体24h动态血压研究中,第10天时anacetrapib组和安慰剂组之间的最小方差为收缩压0.60mmHg(1mmHg≈0.133kPa)(90%CI-1.54~2.74;P=0.634),舒张压0.47mmHg(90%CI-0.90~1.84;P=0.561)。
结论Anacetrapib升高HDL-C的作用似乎远大于其他同类试验药物,而降低LDL-C的作用似乎与他汀类药物相似。尽管调脂作用强于其他同类药物,但anacetrapib似乎并不升高血压,这提示有效抑制CETP本身并不会使血压升高。 | Rajesh Krishna Matt S Anderson Arthur J Bergman Bo Jin Marissa Fallon Josee Cote Kim Rosko Cynthia Chavez-Eng Ryan Lutz Daniel MBloomfi eld Maria Gutierrez James Doherty Fredrick Bieberdorf Jeffrey Chodakewitz Keith M Gottesdiener John A Wagner 王亭忠(译) | 2008 | 世界临床医学2008，2，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员